Navigation Links
Chest Physicians Now Suggest Early Intervention for Certain Blood Clots in DVT
Date:7/29/2008

y, skin ulcerations and post-thrombotic syndrome.

"The publication of the new 2008 ACCP guidelines suggesting the use of pharmacomechanical thrombolysis clearly establishes a new standard for thrombolytic therapy. We believe the Trellis(R) Isolated Pharmacomechanical Thrombolysis method provides the best available combination of safety and efficacy," remarked Scott Cramer, President and CEO of Bacchus Vascular, Inc.

Isolated pharmacomechanical thrombolysis using the Trellis Peripheral Infusion System from Bacchus Vascular, Inc. to deliver thrombolytic directly into a desired treatment segment has proven to be a rapid, effective and safe method of treating patients with acute DVT. The Trellis device is the only DVT treatment system that isolates the thrombus and targets the thrombolytic treatment.

About Bacchus Vascular

Bacchus Vascular, Inc. is a privately held medical device company dedicated to the treatment of peripheral vascular disease. Dr. Thomas Fogarty, a noted inventor and cardiovascular surgeon, founded the company with the vision of transforming blood clot removal from peripheral blood vessels into a fast, simple, minimally-invasive catheter-based procedure. Thousands of patients suffering from DVT and other occlusive vascular diseases have been treated worldwide to date using the company's Trellis(R) Peripheral Infusion System and other products.

For more information, visit http://www.bacchusvascular.com.

For complete information on the new ACCP VTE Guidelines, visit: http://www.TheNewGuidelines.org.


'/>"/>
SOURCE Bacchus Vascular, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Rochester Medical Announces Third Quarter 2008 Earnings Conference Call July 31, 2008
2. Medline Signs 3-Year Purchasing Agreement for Mouth Rinse From Chester Labs
3. Rochester Medical Announces Second Quarter 2008 Earnings Conference Call April 29, 2008
4. Former Manchester City Lord Mayor Has Hope Restored at New Beike Stem Cell Facility
5. Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter
6. Actelion Announces Multiple Presentations on Tracleer(R) and the REVEAL Registry at CHEST 2007
7. Cardicas C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries
8. National ePrescribing Patient Safety Initiative Supports Senates Call for Physicians to Adopt Electronic Prescribing, Improving Patient Safety
9. Ortho Biotech, L.P. and Centocor, Inc. Alert Authorized Distributors and Prescribing Physicians About Stolen Product
10. Lilly Backs Federal Legislation to Inform the Public on Payments to Physicians
11. More Than 700 Physicians and Administrators Participate in the Visian ICL Growth Program(TM) Launch
Post Your Comments:
*Name:
*Comment:
*Email:
Other Biology Technology:Improving an Integral Part of the Lab: Vacuum 2Improving an Integral Part of the Lab: Vacuum 3Improving an Integral Part of the Lab: Vacuum 4Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 2Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 3Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 4Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 5Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 6Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 7Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 8Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 9FLIPR Calcium 3 Assay Kit - An Optimal No-Wash Fluorescence Calcium Indicator Reagent for Non-Optimal Calcium Responses 2FLIPR Calcium 3 Assay Kit - An Optimal No-Wash Fluorescence Calcium Indicator Reagent for Non-Optimal Calcium Responses 3FLIPR Calcium 3 Assay Kit - An Optimal No-Wash Fluorescence Calcium Indicator Reagent for Non-Optimal Calcium Responses 4FLIPR Calcium 3 Assay Kit - An Optimal No-Wash Fluorescence Calcium Indicator Reagent for Non-Optimal Calcium Responses 5FLIPR Calcium 3 Assay Kit - An Optimal No-Wash Fluorescence Calcium Indicator Reagent for Non-Optimal Calcium Responses 6